AbbVie Nearing a $10.9B Deal to Buy Apogee Thera (ABBV:NYSE)
7 Articles
7 Articles
AbbVie is close to a deal to buy Apogee Therapeutics, a maker of drugs for inflammatory diseases, for nearly $11 billion, in what would be the largest acquisition of a complementary business by the pharmaceutical company in more than five years. Exclusive content for subscribers. For full access, follow the link to the article and register.
The major American pharmaceutical company AbbVie is close to acquiring industry peer Apogee Therapeutics for nearly 11 billion dollars, according to the business newspaper Financial Times. The acquisition may be announced as early as Monday. It would then become the second billion-dollar deal in the pharmaceutical sector in a short time.
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
The pharmaceutical giant from the USA apparently plans to purchase Apogee Therapeutics. The offer represents a significant bonus.
Coverage Details
Bias Distribution
- 60% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
